Apollo Hospitals Enterprise Ltd has announced a scheduled Board of Directors meeting on November 6, 2025, to review and approve the company's unaudited financial results for the second quarter of the fiscal year 2026. This meeting will cover the financial performance for both the three and six months ended September 30, 2025.

Key Details of the Announcement

Trading Window Closure

In compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct for Prevention of Insider Trading, Apollo Hospitals has implemented a trading window closure. This measure is designed to prevent insider trading and ensure fair market practices.

The company has taken steps to inform relevant stock exchanges about the scheduled board meeting and trading window closure. This proactive communication aligns with the regulatory requirements outlined in the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Investors and market participants are advised to take note of these dates, particularly the trading window closure period, to ensure compliance with regulatory guidelines. The financial results, once approved and announced, will provide valuable insights into Apollo Hospitals' performance for the first half of the fiscal year 2026.

Apollo Hospitals Enterprise Limited , a leading healthcare provider in India, has achieved a significant milestone in its corporate restructuring efforts. The company recently received approval from the Competition Commission of India (CCI) for its proposed composite scheme of arrangement involving multiple entities within the Apollo group.

Key Highlights

• The Competition Commission of India granted approval on September 23, under Section 31(1) of the Competition Act, 2002.
• The composite scheme involves Apollo Hospitals Enterprise Limited, Apollo Healthco Limited, Keimed Private Limited, and Apollo Healthtech Limited.
• The scheme was initially approved by Apollo Hospitals' board of directors on June 30.
• The approval is a crucial step, but the scheme remains subject to other necessary statutory and regulatory approvals.

Details of the Composite Scheme

The approved composite scheme of arrangement is structured as follows:

1. Apollo Healthco Limited (AHL) is designated as 'Transferor Company 1'
2. Keimed Private Limited is designated as 'Transferor Company 2'
3. Apollo Healthtech Limited is designated as the 'Resultant Company'

This strategic move is being executed under Sections 230 to 232 of the Companies Act, 2013, and is in compliance with SEBI regulations and other applicable guidelines.

CCI Approval Process

The Competition Commission of India reviewed the proposed combination after receiving a notice filed by Apollo Healthtech Limited, Apollo Healthco Limited, and Keimed Private Limited on July 30. The notice was registered under number C-2025/07/1309.

In its meeting held on September 23, the CCI considered and subsequently approved the proposed combination under Section 31(1) of the Competition Act, 2002. The company is currently awaiting a certified copy of the CCI's detailed order.

Implications and Next Steps

While this approval from the CCI marks a significant step forward for Apollo Hospitals' restructuring plans, it's important to note that the scheme still requires additional approvals. The company will need to secure other necessary statutory and regulatory clearances before the composite scheme can be fully implemented.

Apollo Hospitals Enterprise Limited has stated that it will continue to keep stakeholders informed of further developments regarding this corporate action through appropriate disclosures in compliance with regulatory requirements.

As this strategic move unfolds, industry observers will be keenly watching how it impacts Apollo Hospitals' operational structure and its position in the competitive healthcare landscape of India.